Esophageal Cancer
A deadly cancer of the food pipe often discovered at an advanced stage, typically causing progressive difficulty swallowing solid foods.
Emergency Management: Esophageal food bolus impaction requiring emergent endoscopic removal. Massive upper GI bleeding from tumor erosion requires urgent endoscopic/angiographic intervention.
Esophageal cancer is a highly aggressive malignant neoplasm originating from the epithelial lining of the esophagus. It is broadly classified into two main histological subtypes: Squamous Cell Carcinoma (SCC) and Adenocarcinoma, which have distinct geographic distributions, risk factors, and locations within the esophagus.
Detailed Overview
Adenocarcinoma typically arises in the lower third of the esophagus from Barrett's esophagus—a metaplastic response to chronic gastroesophageal reflux disease (GERD). Squamous cell carcinoma occurs predominantly in the upper and middle thirds and is strongly linked to tobacco and alcohol use. Due to the esophagus lacking a serosal layer and possessing an extensive submucosal lymphatic network, tumors spread rapidly to regional lymph nodes and adjacent mediastinal structures. Consequently, most patients present with advanced, incurable disease.
Epidemiology & Demographics
It is the 8th most common cancer and the 6th leading cause of cancer-related deaths worldwide. SCC is most common globally (especially in the Asian 'esophageal cancer belt'), while Adenocarcinoma is now the predominant subtype in Western countries. It occurs mostly in men over the age of 60.
Etiological Mechanism
Adenocarcinoma is driven by chronic acid exposure leading to Barrett's esophagus (intestinal metaplasia), which progresses to dysplasia and carcinoma. SCC is driven by chronic mucosal irritation from carcinogens (tobacco, alcohol) or thermal injury (hot beverages), leading to squamous dysplasia.
Primary Causes
Barrett's Esophagus (Adenocarcinoma)
Tobacco Smoking (Both, but primarily SCC)
Heavy Alcohol Consumption (SCC)
Achalasia (SCC)
In Adenocarcinoma, chronic gastric acid and bile salt reflux cause damage to the normal stratified squamous epithelium of the distal esophagus. The tissue adapts by undergoing metaplasia to a columnar phenotype with goblet cells (Barrett's esophagus). Mutations in p53 and over-expression of HER2 and EGFR drive progression to low-grade dysplasia, high-grade dysplasia, and invasive adenocarcinoma. In SCC, chronic noxious stimuli (smoke, alcohol) cause genetic alterations (p53, cyclin D1) in squamous cells, leading to dysplasia. Because the esophagus lacks a serosa, tumors easily invade the trachea, aorta, and pericardium.
Diagnostic Criteria & Guidelines
Diagnosis is established via Upper Endoscopy (EGD) with direct visualization and multiple forceps biopsies confirming malignant cells (adenocarcinoma or SCC). Clinical staging is then required using EUS and PET/CT to determine resectability.
For resectable locally advanced disease (Stage II/III): Neoadjuvant chemoradiation (e.g., CROSS trial regimen: Carboplatin/Paclitaxel with 41.4 Gy radiation) followed by surgical resection (Esophagectomy). For very early stage (T1a): Endoscopic mucosal resection (EMR).
Second-Line & Adjunctive Therapy
For unresectable or Stage IV disease: Palliative systemic chemotherapy (Fluorouracil + Oxaliplatin). Addition of targeted therapy (Trastuzumab) if HER2 positive. Immunotherapy (Nivolumab or Pembrolizumab) combined with chemotherapy is now standard for PD-L1 positive advanced tumors.
Surgical & Procedural Management
Esophagectomy (Ivor Lewis or minimally invasive). Involves removing the affected esophagus and regional lymph nodes, and reconstructing the GI tract by pulling the stomach up into the chest to form a neo-esophagus.
Patient Counseling & Advice
Prepare the patient for the high likelihood of requiring a feeding tube (J-tube) during chemoradiation. Emphasize that surgery carries a long, difficult recovery with permanent changes to eating habits (dumping syndrome, reflux).
Follow-Up & Monitoring Schedule
Surveillance includes clinical visits every 3-6 months for the first 2 years, often with CT chest/abdomen and EGD if symptoms arise, to monitor for local recurrence or metastasis.
Preventive Strategies
Screening EGD for patients with chronic GERD > 5 years plus risk factors (white male, >50, obese) to identify and ablate Barrett's esophagus before cancer develops. Avoidance of tobacco and heavy alcohol use.
Overall poor. The 5-year survival rate is approximately 20%. If diagnosed at an early, localized stage, 5-year survival approaches 45%, but for metastatic disease, it is <5%.